TFGT
ADCT icon

TS Financial Group (TSFG)’s ADC Therapeutics ADCT Stock Holding History

TS Financial Group (TSFG)’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100
Closed – – 803
2025
Q3 		$0 Hold
100
– – ﹤0.01% 819
2025
Q2 		$0 Hold
100
– – ﹤0.01% 796
2025
Q1 		$0 Buy
+100
New +$170 ﹤0.01% 794

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TS Financial Group (TSFG)'s ADCT Position: Q4 2025 in Review

TS Financial Group (TSFG) sold out of ADC Therapeutics (ADCT) in Q4 2025, closing a stake of 100 shares.

TS Financial Group (TSFG) first reported a position in ADCT in Q1 2025 and held it in 3 quarters. The position peaked at $0 in Q3 2025. 115 funds tracked by Wall St. Rank hold ADCT as of Q4 2025.

  • TS Financial Group (TSFG) reported no remaining ADC Therapeutics position as of Q4 2025 after selling out during the quarter.
  • TS Financial Group (TSFG) sold 100 ADC Therapeutics shares in Q4 2025.
  • TS Financial Group (TSFG) first reported a position in ADC Therapeutics in Q1 2025 and held it in 3 quarters.
  • TS Financial Group (TSFG)'s ADC Therapeutics position peaked at $0 in Q3 2025.
  • 115 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2025.

Based on TS Financial Group (TSFG)'s 13F filing for Q4 2025, filed 4 Feb 2026.